Pyritinol treatment of SDAT patients: evaluation by psychiatric and neurological examination, psychometric testing and rCBF measurements.
A group of 26 patients with the diagnosis of Senile Dementia of Alzheimer type (SDAT) was included by random assignment in a double-blind, cross-over trial of pyritinol versus placebo. The patients had a mild to moderate degree of dementia. Psychiatric and neurological examination, psychometric testing, and measurement of the regional cerebral blood flow (rCBF) at rest and during mental activation were used to assess treatment effects. The results of the study showed that pyritinol was associated with a significant improvement in cognitive performance. RCBF data showed that treatment with pyritinol normalized the pattern of blood flow increase during activation and improved the score on the test used for activation.
Knezevic
S
S
Department of Neurology, University Hospital Centre, Zagreb, Yugoslavia.
Mubrin
Z
Z
Risberg
J
J
Vucinic
G
G
Spilich
G
G
Gubarev
N
N
Wannenmacher
W
W
D000368:Aged; D000369:Aged, 80 and over; D000544:Alzheimer Disease / Q000188:drug therapy* / Q000523:psychology; D001143:Arousal / Q000187:drug effects; D002540:Cerebral Cortex / Q000098:blood supply; D002560:Cerebrovascular Circulation / Q000187:drug effects*; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008297:Male; D008606:Mental Processes / Q000187:drug effects; D009483:Neuropsychological Tests; D011725:Pyridines / Q000627:therapeutic use*; D011746:Pyrithioxin / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic
D011725:Pyridines; D011746:Pyrithioxin